NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is claimed to be the
The post Zydus secures DCGI approval for Saroglitazar to treat liver disease appeared first on Pharmaceutical Business review.
Original Article: Zydus secures DCGI approval for Saroglitazar to treat liver disease